期刊文献+

丁酸钠对子宫内膜癌细胞增殖及NDRG1蛋白表达的影响 被引量:2

The influences of sodium butyrate on endometrial cancer cell proliferation and the expression of NDRG1
下载PDF
导出
摘要 目的探讨组蛋白去乙酰化酶抑制剂丁酸钠(NaB)对子宫内膜癌细胞株HEC-2B增殖及N-myc下游调节基因1(NDRG1)蛋白表达的影响。方法采用MTT比色法检测不同浓度的NaB处理HEC-2B细胞48、72h后细胞的生长情况;荧光倒置显微镜下观察NaB处理48h后细胞的形态改变;Western blotting法检测NaB处理48h后细胞中NDRG1蛋白的表达情况。结果 NaB能够抑制HEC-2B细胞的增殖,并呈浓度和时间依赖性(P<0.05)。不同浓度NaB作用48h后,荧光倒置显微镜下HEC-2B细胞出现细胞凋亡的特征性改变。随着NaB浓度的增加,HEC-2B细胞中NDRG1蛋白的表达水平逐渐下调。结论 NaB能够抑制子宫内膜癌HEC-2B细胞的增殖,可能与下调NDRG1蛋白的表达有关。 Objective To investigate the anti-proliferative effects induced by sodium butyrate (NaB) on human endometrial carcinoma HEC-2B cell line and its influence on N-myc downstream regulated gene 1 ( NDRG1 ) expression. Methods The HEC-2B cells were exposed to various concentrations of NaB for 48 and 72h. The cell proliferation was evaluated by MTT assay. The morpholog- ical changes of the HEC-2B cells were observed by inverted fluorescence microscope. The expression of NDRG1 protein was determined by Western blotting method. Results MTI" assay showed that NaB inhibited the growth of HEC-2B cell line in a dose- and time-de- pendent manner in vitro ( P 〈 0. 5 ). After NaB treatment for 48h, evident morphological changes with pathognomonic feature of apoptosis were observed. Western blotting showed that the expression of NDRG1 protein were gradually down-regulated with the increasing of NaB concentration. Conclusion NaB can significantly inhibit the growth of human endometrial carcinoma in vitro and its mechanism may be related to the down-regulation of NDRG1 protein expression.
作者 陈玲 耿晓星
出处 《临床肿瘤学杂志》 CAS 2013年第6期490-493,共4页 Chinese Clinical Oncology
基金 黑龙江省教育厅科学技术研究项目(12511343)1
关键词 丁酸钠 子宫内膜癌 HEC-2B细胞 N-myc下游调节基因1 Sodium butyrate Endometrial cancer HEC-2B cell line N-myc downstream regulated gene 1 (NDRG1)
  • 相关文献

参考文献22

  • 1Hess-Stumpp H. Histone deacetylase inhibitors and cancer: from cell biology to the clinic [ J]. Eu J Cell Biol,2005,84 (2-3) :109 -121.
  • 2Marks PA, Xu WS. Histone deacetylase inhihitors: potential in cancer therapy[ J]. J Cell Biochem ,2009,107 (4) :600 - 608.
  • 3Jiang S,Dowdy SC,Meng XW, et al. Histone deacetylase inhibi- tots induce apoptosis in both Type I and Type lI endometrial cancer cells[J]. Gynecol Oncol,2007,105 (2) :493 - 500.
  • 4Chen S, Han YH, Zheng Y, et al. NDRG1 contributes to retinoic acid-induced differentiation of leukemic ceils [ J ]. Leuk Res, 2009,33(8) :1108 - 1113.
  • 5Le NT, Richardson DR. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and me- tastasis suppressor gene : a link between iron metabolism and pro- liferation [ J ]. Blood,2004,104 (9) :2967 - 2975.
  • 6Jemal A, Bray F, Center MM, et al. Global cancer stalistcs[ J]. CA Cancer J Clin,2011,61 (2) :69 -90.
  • 7Marks PA, Miller T, Richon VM. Histone deacetylases[J]. Curr Opin Pharmaco1,2003,3 (4) :344 - 351.
  • 8Glozak MA, Seto E. Histone deaeetylases and cancer[J] Oneo- gene ,2007,26 ( 37 ) :5420 - 5432.
  • 9Joes PA, Baylin SB. The epigenomies of cancer[ J]. Ce11,2007, 128(4) :683 -692.
  • 10Blackwell L,Norris J,Suto CM, et al. The use of diversity profi- ling to characterize chemical modulators of the bistone deaeety- lases[ J]. Life Sci,2008,82(21-22) :1050 - 1058.

二级参考文献22

  • 1高岭,董明敏,曹华,程秀莲.丁酸钠对Hep-2细胞的生长抑制和诱导凋亡作用及其对端粒酶活性的影响[J].中华耳鼻咽喉头颈外科杂志,2007,42(1):58-63. 被引量:2
  • 2Pulukuri SM, Gorantla B, Rao J S. Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator[J]. J Biol Chem, 2007,282(49) :35594-35603.
  • 3Belotti D, Calcagno C, Garofalo A, et al. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion[J]. Mol Cancer Res,2008,6(4):525-534.
  • 4Duncan TJ, Al-Attar A, Rolland P, et al. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies [J]. Clin Cancer Res,2008,14(10) : 3030-3035.
  • 5Hu Z,Fan C, Livasy C, He X, et al. A compact VEGF signature associated with distant metastases and poor outcomes[J]. BMC Med,2009,7:9.
  • 6Muhlethaler-Mottet A, Meier R, Flahaut M, et al. Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells[J]. Mol Cancer,2008,12(7) :55.
  • 7Heider U, Kaiser M, Sterz J, et al. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma [J]. Eur J Haematol, 2006,76 ( 1 ) : 42-50.
  • 8Holger HS. Histone deacetylase inhibitors and cancer: from cell biology to the clinic[J]. Eu J Cell Biol,2005,84:109-121.
  • 9Marks PA, Miller T, Richon VM. Histone deacetylases[J]. Curr Opin Pharmacol,2003,3(4)=344 351.
  • 10Rodriguez Salvador J, Armas-Pineda C, Perezpena-Diazconti M,et al. Effect of sodium butyrate on pro-matrix metalloproteinase-9 and -2 differential secrelion in pediatric tumors and cell lines[J]. J Exp Clin Cancer Res,2005,24(3) :463-473.

共引文献2

同被引文献11

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部